Akero Therapeutics Inc banner

Akero Therapeutics Inc
NASDAQ:AKRO

Watchlist Manager
Akero Therapeutics Inc Logo
Akero Therapeutics Inc
NASDAQ:AKRO
Watchlist
Price: 54.65 USD Market Closed
Market Cap: $4.5B

Wall St Price Targets

AKRO Price Targets Summary
Akero Therapeutics Inc

There are no price targets for AKRO.
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
Akero Therapeutics Inc Competitors:
Price Targets
VRNS
Varonis Systems Inc
7% Upside
EXPO
Exponent Inc
48% Upside
TTD
Trade Desk Inc
48% Upside
ZEAL
Zealand Pharma A/S
99% Upside
FBIZ
First Business Financial Services Inc
11% Upside

Revenue
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Gross Profit
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is AKRO's stock price target?
Not Available

AKRO does not have any price targets made by Wall Street professionals.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett